StockData
enGene Therapeutics Inc. logo

enGene Therapeutics Inc. (ENGN) stock

ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30
$1.72−0.17 (-8.99%)

Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%

enGene Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

enGene Therapeutics's price to book ratio was 0.5× on Nov 11, 2026, against 2.1× a year earlier. Over the last 3 years it ranged from 0.4× to 6.3×, with a median of 1.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.5×−2.3
2025Dec 31, 20252.8×+1.6
2024Dec 31, 20241.2×−1.7
2023Dec 29, 20233.0×–

More enGene Therapeutics figures

See a number that looks wrong?